Raymond James & Associates’s 89bio ETNB Stock Holding History

Raymond James & Associates’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.69M	Buy	227,953 +45,010	+25%	+$378K	﹤0.01%	2330
2024 Q2	$1.47M	Buy	182,943 +47,670	+35%	+$426K	﹤0.01%	2347
2024 Q1	$1.57M	Buy	135,273 +26,870	+25%	+$297K	﹤0.01%	2310
2023 Q4	$1.21M	Buy	108,403 +5,415	+5%	+$49.8K	﹤0.01%	2411
2023 Q3	$1.59M	Buy	102,988 +3,464	+3%	+$58.1K	﹤0.01%	2154
2023 Q2	$1.89M	Buy	99,524 +29,421	+42%	+$517K	﹤0.01%	2093
2023 Q1	$1.07M	Buy	70,103 +30,150	+75%	+$393K	﹤0.01%	2419
2022 Q4	$509K	Sell	39,953 -554	-1%	-$4.98K	﹤0.01%	2891
2022 Q3	$235K	Buy	40,507 +21,000	+108%	+$92.3K	﹤0.01%	3345
2022 Q2	$63K	Buy	+19,507	New	+$58.9K	﹤0.01%	3759
2021 Q2	–	Sell	-22,985	Closed	-$544K	–	4121
2021 Q1	$544K	Buy	+22,985	New	+$531K	﹤0.01%	2958

Other funds holding ETNB

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Raymond James & Associates's ETNB Position: Q3 2024 in Review

Raymond James & Associates increased its 89bio (ETNB) stake by 25% in Q3 2024, buying an estimated $378K and bringing the position to 227,953 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2330.

Raymond James & Associates first reported a position in ETNB in Q1 2021 and has held it in 11 quarters since. The position peaked at $1.89M in Q2 2023. 144 funds tracked by Wall St. Rank hold ETNB as of Q3 2024.

Raymond James & Associates held 227,953 shares of 89bio worth $1.69M as of Q3 2024.
Raymond James & Associates bought 45,010 89bio shares in Q3 2024, an estimated $378K.
89bio made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2330 holding.
Raymond James & Associates first reported a position in 89bio in Q1 2021 and has held it in 11 quarters since.
Raymond James & Associates's 89bio position peaked at $1.89M in Q2 2023.
144 funds tracked by Wall St. Rank held 89bio as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.